March 02, 2023 — 07:58 am EST

      Written by
                        RTTNews.com for                             
        




RTTNews ->


(RTTNews) - Avadel Pharmaceuticals plc. (AVDL) said Thursday it has submitted an amendment to the U.S. Food and Drug Administration requesting final approval for Lumryz for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy.
The submission follows a unanimous 3-0 panel decision by the United States Court of Appeals for the Federal Court on February 24, affirming the previous ruling from the United States District Court for the District of Delaware, ordering Jazz Pharmaceuticals to delist its U.S. Patent No. 8,731,963 from FDA's Orange Book.
Jazz submitted its request to delist the REMS Patent to FDA on February 28.
For More Such Health News, visit rttnews.com 
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

© 2023, Nasdaq, Inc. All Rights Reserved.










To add symbols:


These symbols will be available throughout the site during your session.
To add symbols:


These symbols will be available throughout the site during your session.